FDA In Brief: FDA Requests Voluntary Withdrawal of Weight-Loss Medication After Clinical Trial Shows an Increased Occurrence of Cancer

FDA is requesting drug manufacturer Eisai Inc. to voluntarily withdraw its weight loss medication Belviq and Belviq XR (lorcaserin) from the U.S. market after a data analysis from a postmarket clinical trial showed that an increased occurrence of cancer.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news